SK87993A3 - Pharmaceutical composition - Google Patents
Pharmaceutical composition Download PDFInfo
- Publication number
- SK87993A3 SK87993A3 SK879-93A SK87993A SK87993A3 SK 87993 A3 SK87993 A3 SK 87993A3 SK 87993 A SK87993 A SK 87993A SK 87993 A3 SK87993 A3 SK 87993A3
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- pharmaceutical composition
- composition according
- formula
- quinone
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 40
- DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 claims abstract description 20
- 229940114118 carminic acid Drugs 0.000 claims abstract description 20
- 235000012730 carminic acid Nutrition 0.000 claims abstract description 20
- 239000004106 carminic acid Substances 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000003085 diluting agent Substances 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 230000009385 viral infection Effects 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 6
- BDJXVNRFAQSMAA-UHFFFAOYSA-N quinhydrone Chemical compound OC1=CC=C(O)C=C1.O=C1C=CC(=O)C=C1 BDJXVNRFAQSMAA-UHFFFAOYSA-N 0.000 claims abstract description 6
- DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 229940052881 quinhydrone Drugs 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 150000004053 quinones Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 6
- 150000004056 anthraquinones Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000000962 organic group Chemical group 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 2
- AYFBGZAKIZLFMY-UHFFFAOYSA-N 3,4,5-trihydroxy-1h-quinolin-2-one Chemical compound N1C(=O)C(O)=C(O)C2=C1C=CC=C2O AYFBGZAKIZLFMY-UHFFFAOYSA-N 0.000 claims 1
- 208000031295 Animal disease Diseases 0.000 claims 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 4
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910006127 SO3X Inorganic materials 0.000 abstract 1
- 229930182482 anthraquinone glycoside Natural products 0.000 abstract 1
- 229940098421 anthraquinone glycoside Drugs 0.000 abstract 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- -1 hydroxy, amino Chemical group 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- RUQPQFLYDCXMGX-UHFFFAOYSA-N Spinochrome E Natural products OC1=C(O)C(O)=C2C(=O)C(O)=C(O)C(=O)C2=C1O RUQPQFLYDCXMGX-UHFFFAOYSA-N 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000003048 aphrodisiac agent Substances 0.000 description 2
- 230000002509 aphrodisiac effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007348 radical reaction Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229930182476 C-glycoside Natural products 0.000 description 1
- 150000000700 C-glycosides Chemical class 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241001415288 Coccidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B1/00—Dyes with anthracene nucleus not condensed with any other ring
- C09B1/02—Hydroxy-anthraquinones; Ethers or esters thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0033—Blends of pigments; Mixtured crystals; Solid solutions
- C09B67/0034—Mixtures of two or more pigments or dyes of the same type
- C09B67/0038—Mixtures of anthraquinones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919103075A GB9103075D0 (en) | 1991-02-13 | 1991-02-13 | Trinitrobenzene derivatives and their therapeutic use |
| PCT/GB1992/000262 WO1992014454A1 (en) | 1991-02-13 | 1992-02-13 | Use of quinones in the treatment of cancer or aids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK87993A3 true SK87993A3 (en) | 1993-12-08 |
Family
ID=10689992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK879-93A SK87993A3 (en) | 1991-02-13 | 1992-02-13 | Pharmaceutical composition |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0499467A3 (cs) |
| JP (1) | JPH06505231A (cs) |
| CN (1) | CN1064407A (cs) |
| AP (1) | AP549A (cs) |
| AU (2) | AU1233992A (cs) |
| BG (1) | BG61025B1 (cs) |
| BR (1) | BR9205642A (cs) |
| CA (1) | CA2104009A1 (cs) |
| CZ (1) | CZ166893A3 (cs) |
| DZ (1) | DZ1559A1 (cs) |
| FI (1) | FI933595A7 (cs) |
| GB (2) | GB9103075D0 (cs) |
| GT (1) | GT199200009A (cs) |
| HU (1) | HUT65634A (cs) |
| IE (1) | IE920464A1 (cs) |
| IL (1) | IL100906A (cs) |
| IN (1) | IN178929B (cs) |
| IS (1) | IS3814A (cs) |
| JO (1) | JO1719B1 (cs) |
| LT (1) | LT3197B (cs) |
| MA (1) | MA22443A1 (cs) |
| MX (1) | MX9200622A (cs) |
| MY (1) | MY131098A (cs) |
| NO (1) | NO932681L (cs) |
| NZ (2) | NZ240487A (cs) |
| OA (2) | OA09535A (cs) |
| SK (1) | SK87993A3 (cs) |
| TN (1) | TNSN92015A1 (cs) |
| WO (1) | WO1992014454A1 (cs) |
| ZA (1) | ZA921037B (cs) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103075D0 (en) | 1991-02-13 | 1991-03-27 | Washington Odur Ayuko | Trinitrobenzene derivatives and their therapeutic use |
| DZ1781A1 (fr) * | 1993-05-21 | 2002-02-17 | Radopah Ltd | Agents d'arylation. |
| IL113025A0 (en) * | 1994-03-17 | 1995-06-29 | Radopath Ltd | Anti-viral and anti-cancer agents |
| ATE188870T1 (de) * | 1994-10-04 | 2000-02-15 | Lohmann Rudolf Lomapharm | Lösungen von anthrachinonen zur parenteralen applikation |
| US7482029B2 (en) | 2005-04-01 | 2009-01-27 | Bionovo, Inc. | Composition for treatment of menopause |
| US7537774B2 (en) * | 2005-12-23 | 2009-05-26 | Orion Therapeautics, Llc | Therapeutic formulation |
| JP2010535815A (ja) | 2007-08-08 | 2010-11-25 | バイオノボ・インコーポレーテッド | モクセイ科トウネズミモチのエストロゲン性抽出物およびその使用 |
| AU2008296136A1 (en) | 2007-09-07 | 2009-03-12 | Bionovo. Inc. | Estrogenic extracts of Scuttelaria barbata D. Don of the Labiatae Family and uses thereof |
| JP2010539085A (ja) | 2007-09-07 | 2010-12-16 | バイオノボ・インコーポレーテッド | マメ科ファミリーのキバナオウギのエストロゲン性抽出物およびその使用 |
| CA2698719A1 (en) | 2007-09-07 | 2009-03-12 | Bionovo, Inc. | Estrogenic extracts of asparagus conchinchinensis (lour.) merr of the liliaceae family and uses thereof |
| EP2060562A1 (en) * | 2007-11-16 | 2009-05-20 | Laboratoire Medidom S.A. | Dioxoanthracene sulphonate derivatives |
| AU2008329902A1 (en) | 2007-11-19 | 2009-06-04 | Bionovo, Inc. | A process of making purified extract of scutellaria barbata D. Don |
| AU2008326426A1 (en) | 2007-11-19 | 2009-05-28 | Bionovo, Inc. | Methods of detecting and treatment of cancers using scuttelaria barbata extract |
| US20090312437A1 (en) * | 2008-06-06 | 2009-12-17 | Bionovo, Inc., A Delaware Corporation | Anthraquinones and Analogs from Rhuem palmatum for Treatment of Estrogen Receptor Beta-Mediated Conditions |
| WO2013055913A2 (en) | 2011-10-14 | 2013-04-18 | Emory University | Pgam1 inhibitors and methods related thereto |
| CZ304335B6 (cs) * | 2012-02-22 | 2014-03-12 | Mikrobiologický ústav AV ČR, v. v. i. | Submerzní kmeny Quambalaria sp. CCM 8372 a CCM 8373, směs naftochinonových barviv jimi produkovaná, způsob jejich produkce a použití |
| EP3824031A1 (en) * | 2018-07-17 | 2021-05-26 | Pili | Anthraquinonic derivatives and their use as colouring agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7708452L (sv) * | 1977-07-22 | 1979-01-23 | Allied Chem | Komposition innehallande en antrakinonforening |
| JPS6054286B2 (ja) * | 1979-09-18 | 1985-11-29 | 江澤 林 | 免疫増強剤 |
| JPS6043210A (ja) * | 1983-08-18 | 1985-03-07 | Tdk Corp | 磁気ヘツド及びその製造方法 |
| DE3431236A1 (de) * | 1984-08-24 | 1986-02-27 | Carnivora-Deutschland GmbH, 7109 Jagsthausen | Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation |
| DE3601065A1 (de) * | 1986-01-16 | 1987-07-23 | Behringwerke Ag | Chinon-derivate als antitumormittel |
| WO1989005141A1 (en) * | 1987-12-10 | 1989-06-15 | Tsumura Juntendo, Inc. | Anti-retroviral drug |
| DE68928964T2 (de) * | 1988-08-16 | 1999-07-29 | The Wellcome Foundation Ltd., London | Neue Naphthochinone und ihre Anwendung als Arzneimittel |
| GB9103075D0 (en) | 1991-02-13 | 1991-03-27 | Washington Odur Ayuko | Trinitrobenzene derivatives and their therapeutic use |
| JPH06501449A (ja) * | 1990-04-03 | 1994-02-17 | ラドパス リミテッド | 癌またはウイル性疾患の治療におけるトリニトロベンゼン類またはカルミン酸の使用 |
| DE4013023A1 (de) * | 1990-04-24 | 1991-11-07 | Lohmann Rudolf Lomapharm | Verwendung von anthrachinonderivaten zur prophylaxe und therapie von viruserkrankungen |
-
1991
- 1991-02-13 GB GB919103075A patent/GB9103075D0/en active Pending
- 1991-11-05 NZ NZ240487A patent/NZ240487A/en unknown
-
1992
- 1992-02-10 IN IN97DE1992 patent/IN178929B/en unknown
- 1992-02-10 IL IL10090692A patent/IL100906A/en not_active IP Right Cessation
- 1992-02-11 NZ NZ241593A patent/NZ241593A/en unknown
- 1992-02-12 MA MA22730A patent/MA22443A1/fr unknown
- 1992-02-12 DZ DZ920016A patent/DZ1559A1/fr active
- 1992-02-12 IS IS3814A patent/IS3814A/is unknown
- 1992-02-12 AP APAP/P/1992/000356A patent/AP549A/en active
- 1992-02-13 MY MYPI92000228A patent/MY131098A/en unknown
- 1992-02-13 WO PCT/GB1992/000262 patent/WO1992014454A1/en not_active Application Discontinuation
- 1992-02-13 SK SK879-93A patent/SK87993A3/sk unknown
- 1992-02-13 CA CA002104009A patent/CA2104009A1/en not_active Abandoned
- 1992-02-13 TN TNTNSN92015A patent/TNSN92015A1/fr unknown
- 1992-02-13 IE IE046492A patent/IE920464A1/en unknown
- 1992-02-13 GB GB9203084A patent/GB2254554B/en not_active Expired - Fee Related
- 1992-02-13 CZ CS931668A patent/CZ166893A3/cs unknown
- 1992-02-13 BR BR9205642A patent/BR9205642A/pt not_active Application Discontinuation
- 1992-02-13 OA OA60150A patent/OA09535A/en unknown
- 1992-02-13 EP EP19920301185 patent/EP0499467A3/en not_active Withdrawn
- 1992-02-13 HU HU9302347A patent/HUT65634A/hu unknown
- 1992-02-13 JO JO19921719A patent/JO1719B1/en active
- 1992-02-13 ZA ZA921037A patent/ZA921037B/xx unknown
- 1992-02-13 CN CN92100817A patent/CN1064407A/zh active Pending
- 1992-02-13 GT GT199200009A patent/GT199200009A/es unknown
- 1992-02-13 JP JP4504180A patent/JPH06505231A/ja active Pending
- 1992-02-13 AU AU12339/92A patent/AU1233992A/en not_active Abandoned
- 1992-02-13 MX MX9200622A patent/MX9200622A/es not_active Application Discontinuation
-
1993
- 1993-02-05 LT LTIP329A patent/LT3197B/lt not_active IP Right Cessation
- 1993-07-26 NO NO93932681A patent/NO932681L/no unknown
- 1993-08-13 BG BG98041A patent/BG61025B1/bg unknown
- 1993-08-13 OA OA60399A patent/OA09810A/en unknown
- 1993-08-13 FI FI933595A patent/FI933595A7/fi not_active Application Discontinuation
-
1996
- 1996-06-11 AU AU55906/96A patent/AU5590696A/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK87993A3 (en) | Pharmaceutical composition | |
| AU2001230977B2 (en) | Combinations for treating neoplasms | |
| US6537990B1 (en) | Combined preparations comprising morpholine anthracyclines and anticancer agent | |
| AU2927999A (en) | Use of epothilones for the treatment of cancer | |
| AU662883B2 (en) | Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases | |
| EP0488718A2 (en) | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine | |
| WO2011026219A1 (en) | Combination therapy for cancer comprising a platinum -based antineoplastic agent and a biocompatible electron donor | |
| CN110664807B (zh) | 一种具有协同抗黑色素瘤功效的药物组合物及其应用 | |
| JP2020537689A (ja) | Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用 | |
| KR100369890B1 (ko) | 설사예방및치료제 | |
| CN106822099A (zh) | 维生素c与苯磺酰胺化合物协同作用的注射用药物组合物 | |
| JP4781624B2 (ja) | Ｒａｎｔｅｓ誘導剤 | |
| KR20210039414A (ko) | 암의 치료를 위한 병용 요법 | |
| EA011573B1 (ru) | Препарат, потенцирующий противоопухолевый эффект, противоопухолевый препарат и способ лечения рака | |
| JPH01313433A (ja) | 抗ｈｉｖ剤 | |
| KR20020009929A (ko) | 간암 치료 및 예방용 의약 조성물 | |
| JPH0667834B2 (ja) | 抗腫瘍剤 | |
| KR100421261B1 (ko) | 피토스핑고신 유도체를 유효 성분으로 포함하는 방사선치료 증진제 | |
| JPS61129124A (ja) | 抗腫瘍剤 | |
| JPH0558892A (ja) | 発癌防止剤 | |
| HRP920891A2 (en) | Quinone preparation | |
| CN113827604A (zh) | 瑞德西韦在制备治疗肿瘤或抗肿瘤转移药物中的应用 | |
| KR20100131457A (ko) | 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제 | |
| HK1068786A (en) | Combined preparations comprising anthracycline derivatives |